Pfizer reorganizes to handle aging consumers and patents

July 11, 2018
Pfizer reorganizes to handle aging consumers and patents
In this Nov. 23, 2015, file photo, the Pfizer logo is displayed at world headquarters in New York. Pfizer says it's going to reorganize the company into three businesses. Pfizer Inc. said Wednesday, July 11, 2018, that a new hospital unit, which will be part of the innovative medicines business, will be for anti-infectives and sterile injectables. There will also be a consumer healthcare business and an off-patent branded and generic established medicines business. (AP Photo/Mark Lennihan, File)

The drugmaker Pfizer, facing an aging population and shifting risks from the loss of patents, is reshaping its structure into three businesses.

The divisions, announced Wednesday, include Innovative Medicines, which will focus on biological science and a new hospital medicines business. An Established Medicines business will include sales for older drugs like the cholesterol pill Lipitor that have lost patent protection.

Lastly, the Consumer Healthcare business will handle over-the-counter medicines.

Innovative Medicines will bring in most of the company's revenue. Pfizer said the growth potential for that business is strong, due in part to an aging population that will create a growing demand for new medicines.

Pfizer Inc., based in New York, expects a significant reduction in the impact of patent protection losses after 2020 following the loss of exclusivity in the U.S. for the pain medicine Lyrica, which is anticipated to occur around December.

CEO Ian Read said in a prepared statement that the reorganization represents a "natural evolution" for Pfizer given the strength of the products they are currently selling and drugs that are in late-stage clinical development.

Read said earlier this year that he expects Pfizer to win 25 to 30 approvals for new medicines or new uses for existing ones through 2022.

The reorganization announced Wednesday will occur at the start of fiscal 2019. The company said it doesn't expect the moves to affect 2018 guidance.

Shares of Pfizer climbed 2 cents to $37.45 before markets opened Wednesday.

Explore further: Pfizer 2Q mixed, maintains 2013 outlook

Related Stories

Pfizer 2Q mixed, maintains 2013 outlook

July 30, 2013
Pfizer's second-quarter net income more than quadrupled, helped by the sale of its animal health business. The world's second-largest drugmaker beat Wall Street's earnings expectations, though revenue continued to decline ...

20 years after Viagra, Pfizer seeks another miracle drug

April 1, 2018
It has been 20 years since Viagra was introduced, and Pfizer is still searching for another drug with as much earning power as the revolutionary blue erection pill.

Pfizer considers consumer business sale

October 10, 2017
Pfizer may be done selling ChapStick, Advil, Robitussin and other brands that people can buy without a prescription.

Pfizer beats Street 2Q forecasts despite big drop in profit

August 2, 2016
Rising sales of Pfizer Inc.'s key new medicines and prospects more drugs will be approved over the next couple years have analysts speculating the biggest U.S. drugmaker won't break up after all.

Pfizer's Q1 net jumps 14 pct., sales just miss expectations

May 1, 2018
Pfizer posted slightly higher sales and a 14 percent jump in profit in the first quarter, thanks to lower restructuring costs and a much-lower tax rate, but its revenue still missed Wall Street expectations.

Pfizer to launch cheaper version of J&J immune drug Remicade

October 18, 2016
Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson & Johnson's blockbuster immune disorder drug, Remicade.

Recommended for you

Rapid response inpatient education boosts use of needed blood-thinning drugs

November 16, 2018
A new study designed to reach hospitalized patients at risk shows that a "real-time" educational conversation, video or leaflet can lower the missed dose rates of drugs that can prevent potentially lethal blood clots in their ...

Drug overdose epidemic goes far beyond opioids, requires new policies

November 7, 2018
Most government-funded initiatives to address the overdose epidemic in the United States have targeted opioids specifically and have neglected other drugs that are increasingly implicated in overdoses, such as cocaine and ...

Zebrafish larvae help in search for appetite suppressants

November 2, 2018
Researchers at the University of Zurich and Harvard University have developed a new strategy in the search for psychoactive drugs. By analyzing the behavior of larval zebrafish, they can filter out substances with unwanted ...

FDA OKs powerful opioid pill as alternative to IV painkiller

November 2, 2018
U.S. regulators on Friday approved a fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals.

Amphetamine-related hospitalizations surged between 2003 and 2015

November 2, 2018
An analysis conducted by Hennepin Healthcare, University of Minnesota School of Public Health and University of Michigan researchers shows amphetamine-related hospitalizations increased more than 270 percent from 2008 to ...

Cocaine-fentanyl overdoses underscore need for more 'test strips' and rapid response

November 1, 2018
Penn Medicine emergency department physicians are calling for more readily available testing strips to identify the presence of fentanyl in patients experiencing a drug overdose, and a rapid, coordinated response among health ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.